HOLX - Hologic buys European molecular diagnostic firm Diagenode

Hologic (HOLX) has acquired Diagenode, a privately held European developer and manufacturer of molecular diagnostic assays and epigenetics products, for ~$159M.Diagenode offers more than 30 real-time PCR tests that are CE-marked to detect bacteria, parasites, and viruses involved in sexually transmitted infections, respiratory diseases, meningitis, and gastroenteritis.Diagenode previously collaborated with HOLX to develop Panther Fusion assays for group B Streptococcus and Bordetella.Diagenode generated more than $30M of revenue in the last 12 months.The acquisition is expected to be approximately break-even to Hologic’s non-GAAP EPS through fiscal 2022, and accretive after that.Press Release

For further details see:

Hologic buys European molecular diagnostic firm, Diagenode